The p53 tumor suppressor protein is frequently mutated in human tumors. It is thought that the p53 pathway is indirectly impaired in the remaining tumors, for example by overexpression of its important regulators Mdm2 and Mdm4, making them attractive targets for the development of anti-cancer agents. Recent studies have suggested that Mdm4 levels determine the sensitivity of tumor cells for anti-cancer therapy. To investigate this possibility, we studied the drug sensitivity of several breast cancer cell lines containing wild-type p53, but expressing different Mdm4 levels. We show that endogenous Mdm4 levels can affect the sensitivity of breast cancer cells to anti-cancer agents, but in a cell line-dependent manner and depending on an intact apoptotic response. Furthermore, treatment with the non-genotoxic agent Nutlin-3 sensitizes cells for doxorubicin, showing that activation of p53 by targeting its regulators is an efficient strategy to decrease cell viability of breast cancer cells. These results confirm a function of Mdm4 in determining the efficacy of chemotherapeutic agents to induce apoptosis of cancer cells in a p53-dependent manner, although additional undetermined factors also influence the drug response. Targeting Mdm4 to sensitize tumor cells for chemotherapeutic drugs might be a strategy to effectively treat tumors harboring wild-type p53.
Introduction
The p53 tumor suppressor protein has a major function in the maintenance of genome integrity. Activation of p53 in response to various signals leads to the transcriptional regulation of genes important for suppressing tumorigenesis. In addition, p53 can induce apoptosis in a transcription-independent manner (Fuster et al., 2007) . The critical function of p53 is reflected by the fact that it is frequently targeted for inactivation and a majority of malignant tumors have acquired mutations that impair the functionality of p53. All together, approximately 50% of all human malignancies harbor mutations in p53, whereas the p53 tumor suppressor pathway is thought to be functionally impaired in the remaining tumors, for example by alterations in the main regulators of p53 (Toledo and Wahl, 2006) .
In unstressed normal cells, p53 is present at low levels because of rapid degradation by the ubiquitin-dependent proteasome pathway (Brooks and Gu, 2006) . Mdm2 is an important regulator of p53 turnover by binding p53 and acting as an E3 ubiquitin ligase (Haupt et al., 1997; Kubbutat et al., 1997) . In addition, binding of Mdm2 to p53 disrupts the interaction between p53 and the transcriptional machinery, thereby antagonizing p53 transcriptional activation (Momand et al., 1992) . Importantly, Mdm2 overexpression has been found in human cancers, in general correlating with the expression of wild-type p53 (Oliner et al., 1992) .
Mdm4, a structural homologue of Mdm2, is also a critical regulator of p53 activity (Shvarts et al., 1996 (Shvarts et al., , 1997 . Unlike Mdm2, Mdm4 has no detectable ubiquitin ligase activity and is, therefore, unable to target p53 for degradation. The primary function of Mdm4 seems to be inhibition of p53-mediated transcriptional activation. In addition, it has been reported that Mdm4 can enhance Mdm2-mediated ubiquitination and degradation of p53 (Stad et al., 2000 . Similar to Mdm2, Mdm4 has been found overexpressed in a significant number of various human tumors and tumor cell lines, in general correlating with the expression of wild-type p53, suggesting that Mdm4 contributes to p53 inactivation during tumorigenesis (Riemenschneider et al., 1999 (Riemenschneider et al., , 2003 Ramos et al., 2001; Danovi et al., 2004; Laurie et al., 2006) . As both Mdm2 and Mdm4 are overexpressed in many tumors that retain wild-type p53, they are attractive targets for the development of anti-cancer agents.
Mdm2 and Mdm4 are both targeted by stress signaling pathways that activate p53 . Genotoxic stress activates damage-responsive kinases such as ATM, which activates p53 in part by direct phosphorylation of p53 itself and also by destabilization and inhibition of its negative regulators (Pereg et al., , 2006 . Therefore, DNA damage potently stimulates p53 activity by eliminating interactions with its two main negative regulators.
However, the use of genotoxic agents in chemotherapy is associated with undesirable and severe side effects (Shapiro and Recht, 2001 ). Other approaches aim at disrupting the binding between Mdm2 and p53 to facilitate wild-type p53 activities. Recently, Nutlin-3 has been identified in a high throughput screen for compounds capable of disrupting Mdm2-p53 interactions (Vassilev et al., 2004) . Nutlin-3 is a small molecule inhibitor that binds Mdm2 in its p53-binding pocket, thereby preventing binding to p53. Consequently, Nutlin-3 treatment results in stabilization of p53 and activation of the p53 pathway. Nutlin-3 was identified based on its ability to inhibit Mdm2-p53 binding. The p53-binding pockets of Mdm2 and Mdm4 show high homology and it has been shown that Nutlin-3 was able to disrupt the binding between Mdm4 and p53 by binding to Mdm4 (Laurie et al., 2006) , although conflicting results have been reported (Hu et al., 2006; Patton et al., 2006; Wade et al., 2006) . Similarly, MI-219 activates p53 by disrupting the Mdm2-p53 interaction. MI-219 was designed based on the crystal structure of the Mdm2-p53 complex, and its ability to inhibit Mdm4-p53 interactions was significantly less efficient (Shangary et al., 2008) . Therefore, despite strong similarities between the p53-binding domains of Mdm4 and Mdm2, minor differences are sufficient to reduce the inhibitory effect of Nutlin-3 on Mdm4-p53 binding. Consistently, some studies have suggested that Mdm4 levels determine the sensitivity of tumor cells for anticancer therapy (Hu et al., 2006; Laurie et al., 2006; Patton et al., 2006; Wade et al., 2006) .
Importantly, Nutlin-3-induced activation of p53 is not associated with induction of DNA damage or damage-induced modifications of p53 (Vassilev et al., 2004) . Owing to these characteristics, Nutlin-3 has been tested for its synergistic effects with existing therapies. It has been shown that treatment with Nutlin-3 is synergistic with genotoxic drugs and radiation in cancer therapy (Barbieri et al., 2006; Cao et al., 2006; CollMulet et al., 2006; Patton et al., 2006) .
We have investigated the function of Mdm4 expression levels in determining the drug sensitivity in a number of breast cancer cell lines containing wild-type p53, but expressing different Mdm4 levels. Manipulation of Mdm4 levels showed that Mdm4 can affect the sensitivity of breast cancer cells to anti-cancer agents, but in a strong cell line-dependent manner and not correlating with initial or remaining Mdm4 levels. The effect of manipulating Mdm4 levels on the drug response of these breast cancer cell lines correlated with the effect on the apoptotic response. These results suggest that expression of proteins involved in the apoptotic pathway(s) together with Mdm4 levels determine drug sensitivity of cancer cells. Identification of such components, which affect drug sensitivity in tumor cells might provide additional targets for further improvement of anti-cancer therapies.
Results
Protein expression profiles of wild-type p53 breast cancer cell lines From a panel of 41 breast cancer cell lines, we have selected cell lines, which express wild-type p53: DU4475, MCF-7, MDA-MB-175VII, MPE600, SK-BR-7, UACC-812, ZR75-1, and ZR75-30 (Supplementary Figure 1 ; Wasielewski et al., 2006) . From this panel of cell lines, protein expression profiles of the p53 and pRB pathways have been analyzed by western blot (Figure 1 ). Although p53 levels of breast cancer cell lines were comparable with the normal breast epithelial cell line MCF-10A1, the expression of either Mdm2 or Mdm4 was increased in breast cancer cell lines. In addition to suppression of the p53 pathway by overexpression of its negative regulators, the pRB tumor suppressor pathway Figure 1 Protein expression profiles of wild-type p53 breast cancer cell lines. Western blot analysis of proteins in the p53 and pRB pathways of a panel of eight wild-type p53 breast cancer cell lines (Wasielewski et al., 2006) ; MCF-10A1 was used as a control for normal breast epithelial cells. Proteins were extracted from cells in exponential growth and cultured under standard conditions. HAUSP and g-tubulin expression were analyzed as loading controls. Protein bands were quantified and normalized for HAUSP expression. Relative expression was calculated by comparing with DU4475 cells. (Figures 2a-d) .
In contrast, cells expressing high levels of Mdm4 were more sensitive to RITA treatment than cells with lower Mdm4 levels ( Figure 2e ). The response to doxorubicin did not clearly correlate to endogenous Mdm4 levels, although again those cells expressing highest Mdm4 levels were least sensitive ( Figure 2f) . Notably, the sensitivity to the Mdm2 inhibitor Nutlin-3 was inversely correlated with endogenous Mdm2 levels, that is cells with relative high endogenous Mdm2 levels (ZR75-1) were more sensitive to Nutlin-3 than cells with lower Mdm2 levels (ZR75-30) ( Figure 2a ). Endogenous Mdm2 levels seemed to be less correlated to sensitivity to the Mdm2 inhibitor RITA (Figure 2e ). Treatment with each of these compounds resulted in induction of p53 and its downstream target Mdm2, but the level of activation varied depending on cell line and treatment ( Figure 3 ). Nutlin-3 treatment resulted in increased levels of the anti-proliferation protein p21 and pro-apoptotic protein PUMA in all tested cell lines, but importantly, no detectable DNA damage response (Ser15 phosphorylation of p53) was observed. In contrast, PALA treatment had little effect on p21 and PUMA levels. RITA treatment showed marginal effects on p53 downstream targets in ZR75-1 cells, which corresponds with the relative resistance in the growth assay. Surprisingly, although ZR75-30 cells were strongly inhibited in growth by RITA, p21 and PUMA levels were not induced after treatment. Treatment with etoposide, doxorubicin, and 5-fluorouracil resulted in increased p21 and PUMA in all tested cell lines except in ZR75-30, which might explain the relative resistance of this cell line to these drugs. Decrease of Mdm4 levels was observed when cells were treated with genotoxic compounds and with RITA in most cell lines. Whether the latter is also regulated through DNA damageinduced degradation of Mdm4 has to be further elucidated, but we did notice Ser15-phosphorylation of p53 on prolonged RITA treatment. Interestingly, the cells showing relative resistance to RITA, ZR75-1 cells, hardly showed a decrease in Mdm4 levels. These results suggest that endogenous Mdm4 levels may affect the sensitivity to some anti-cancer drugs.
As all tested anti-cancer drugs activated p53, it was determined whether p53 activation would be required for the drug-induced growth inhibition. Therefore, p53 was knocked down using short hairpin RNA (shRNA) targeting p53 in these breast cancer cell lines (Figure 3 ). Nutlin-3-induced growth arrest/apoptosis was completely rescued in all cell lines with p53 knock down, which was accompanied by a strongly reduced or complete lack of induction of p53-target genes. In addition, knock down of p53 resulted in a partial, but significant rescue of the doxorubicin-mediated growth inhibition in all tested cell lines. Although the induction of p53 downstream targets by PALA, RITA, etoposide, and 5-FU was strongly reduced on p53 knock down in all cell lines, rescue of drug-induced growth inhibition by p53 knock down was cell line dependent.
Effect of Mdm4 levels on sensitivity to Nutlin-3
The results presented above suggest a correlation between endogenous Mdm4 levels in tumor cells, inhibiting p53, and their sensitivity to Nutlin-3. To investigate this possibility in more detail, Mdm4 levels were manipulated by either knocking down endogenous Mdm4 or by ectopic overexpression using lentiviral expression vectors. Ectopic overexpression of Mdm4 hardly affected proliferation of these cell lines. In contrast, reducing Mdm4 levels significantly reduced the proliferative capacity of all tested cell lines (Supplementary Figure 2) . In colony-forming assays, we found that, as expected, growth inhibition by Mdm4 knock down is p53 dependent (data not shown). Furthermore, reducing Mdm4 levels significantly rendered some cell lines more sensitive to Nutlin-3 treatment, but in a cell line-dependent manner and not correlating with initial Mdm4 levels. In addition, in cell lines, which were sensitized for Nutlin-3 by Mdm4 knock down, that is MCF-7 and ZR75-1, overexpression of Mdm4 significantly reduced responsiveness to Nutlin-3 (Figures 4a and c) . Vice versa, Mdm4 overexpression had no significant effect on Nutlin-3 sensitivity of MPE600 and ZR75-30 cells, which also showed no effect on Mdm4 knock down (Figures 4b and d) . The observed differences in Nutlin-3-mediated effects on manipulation of Mdm4 levels in proliferation assays could not be directly correlated with a distinct regulation of expression of the tested p53 targets. For example, on knock down of Mdm4, p21 and PUMA levels were both increased in MCF-7 and MPE600, although sensitization for Nutlin-3 in cell viability assays was only observed in MCF-7 and not in MPE600 (Figures  4a and b) . In ZR75-1, PUMA levels were increased on Mdm4 knock down (Figure 4c ). Although ectopic overexpression of Mdm4 resulted in decreased p21 levels in all tested cell lines, PUMA levels were slightly decreased only in the two cell lines, which did not show rescue of Nutlin-3-mediated growth inhibition on Mdm4 overexpression. Although Nutlin-3-induced Mdm2 levels were enhanced in Mdm4 knock down cells, no correlation was found with Nutlin-3 hypersensitivity after Mdm4 knock down. Nevertheless, observed effects were dependent on p53, as specific knock down of p53 protected cells against Nutlin-3. These results suggest that Mdm4 protein levels can influence the sensitivity of cells to Nutlin-3 in a p53-dependent manner, but no direct correlation between Mdm4 levels and drug sensitivity could be established.
Effect of Mdm4 levels on Nutlin-3-induced apoptosis
The distinct regulation of two main p53-targets p21 and PUMA could not explain why sensitivity to Nutlin-3 Figure 2 Drug sensitivity of breast cancer cells to various anti-cancer drugs. MCF-7, MPE600, ZR75-1, and ZR75-30 were counted and seeded for proliferation assay. Cells were treated with (a) 10 mM Nutlin-3, (b) 100 mM PALA, (c) 5 mM etoposide, (d) 10 mM 5-fluorouracil, (e) 0.1 mM RITA, or (f) 1 mM doxorubicin. Cell viability was measured 0, 24, 48, and 72 h after drug treatment using the WST-1 assay. Relative cell numbers were determined by calculating the OD450 of drug-treated cells relative to mock-treated cells of the same transduction from the same day of treatment. The results are expressed as mean ± s.d. of triplicate cultures and representative of two independent experiments.
Regulation of drug response by Mdm4
S Lam et al Effect of Mdm4 levels on sensitivity to genotoxic drugs The data presented in Figure 2 also suggest some correlation between endogenous Mdm4 levels in tumor cells and their sensitivity to genotoxic agents. To investigate this possibility in more detail, Mdm4 levels were reduced by shRNA, and cells were treated with doxorubicin. The growth of sh-ctrl cells is inhibited by doxorubicin, but doxorubicin treatment of Mdm4 knock down cells hardly resulted in further growth inhibition ( Figure 6 ). Although doxorubicin inhibited cell growth stronger than Nutlin-3, no PARP cleavage was detected in MCF-7 and MPE600 after doxorubicin treatment (Figures 6a and b) . In contrast, PARP cleavage was observed after doxorubicin treatment in ZR75-1 and ZR75-30. Interestingly, in ZR75-30 cells, PARP cleavage was even decreased in Mdm4 knock down cells compared with sh-ctrl cells, both after Nutlin-3 and doxorubicin treatment (Figures 6c and d ). This correlates with the relative resistance of Mdm4 knock down ZR75-30 cells for doxorubicin treatment.
In addition, reducing Mdm4 protein levels also did not sensitize cells for 5-fluorouracil (data not shown).
Effect of Nutlin-3 and doxorubicin on cellular growth
As knock down of p53 was only able to significantly rescue the growth inhibitory effects of Nutlin-3 and doxorubicin (Figure 3 ), these drugs were used for further study. Treatment with Nutlin-3 completely inhibited cell growth of MPE600, ZR75-1, and ZR75-30 cells, whereas growth of MCF-7 cells was severely slowed down (Supplementary Figure 3) . Treatment with doxorubicin strongly reduced cell viability in all cell lines. Similar to most chemotherapeutic agents, doxorubicin treatment can be accompanied by severe side effects. This favors a reduction of the dose of doxorubicin to prevent the side effects without losing its effect as anti-cancer drug. As the action of doxorubicin is partially dependent on activation of p53 and the non-genotoxic agent Nutlin-3 is a potent inducer of p53, cells were treated with a combination of both compounds. Combining Nutlin-3 and doxorubicin indeed resulted in increased cell death, even with concentrations of doxorubicin that by itself had very little effect on cell survival (Supplementary Figure 3) . Moreover, the combined effect of Nutlin-3 and doxorubicin on cell viability was synergistic in MCF-7 and ZR75-1 (Figures 7a and c) ; in MPE600 and ZR75-30, the effect of the combination was additive (Figures 7b  and d) . The observed effects on cellular level were Figure 4 Effect of Mdm4 levels on sensitivity to Nutlin-3. (a) MCF-7, (b) MPE600, (c) ZR75-1, and (d) ZR75-30 were infected with sh-control, sh-Mdm4, sh-p53, or Mdm4 expression lentiviruses. Four days after transduction, cells were counted and seeded for proliferation assay. After 24 h, cells were treated with 10 mM Nutlin-3. Cell viability was measured 0, 24, 48, and 72 h after drug treatment using the WST-1 assay. Relative cell numbers were determined by calculating the OD450 of drug-treated cells relative to mock-treated cells of the same transduction from the same day of treatment. The results are expressed as mean ± s.d. of triplicate cultures and representative of at least three independent experiments, *Po0.05, **Po0.01, ***Po0.001 compared with sh-control cells at the same day. For the analysis of protein levels by western blot, cells were harvested after 24 h of treatment with 10 mM Nutlin-3. HAUSP expression was analyzed as loading control. Figure 5 Effect of Mdm4 levels on PARP cleavage. MCF-7, MPE600, ZR75-1, and ZR75-30 were infected with sh-control, sh-Mdm4, or sh-p53 lentiviruses. Four days after transduction, cells were treated with 10 mM Nutlin-3. After 24 h of incubation, cells were harvested for total protein extracts. PARP cleavage was analyzed by western blot. Protein bands were quantified and normalized for g-tubulin expression. The results are expressed as mean ± s.d. of three independent experiments, *Po0.05, **Po0.01, ***Po0.001 compared with mock-treated sh-control cells, NS ¼ not significant. Regulation of drug response by Mdm4 S Lam et al accompanied with stronger induction of p53 and its downstream targets Mdm2, p21, and PUMA ( Figure 7e ). In addition, phosphorylation of p53 at Ser15 and Ser46, indication of, respectively, DNA damage and apoptotic responses, was increased in combination of Nutlin-3 and doxorubicin compared with single drug treatment. Moreover, in normal breast epithelial cells, we did not observe any synergistic effect of Nutlin-3 and doxorubicin on cell survival (Supplementary Figure 4) . Thus, in combination with Nutlin-3, a low dose of doxorubicin was sufficient to achieve the same effect as a higher single dose of doxorubicin. Moreover, treatment with this combination can result in a more efficient decrease in cell viability of breast cancer cells. Relative expression was calculated by comparing with mock-treated cells; pSer15-p53 and pSer46-p53 were compared with total p53 levels; ND ¼ not detectable.
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Regulation of drug response by Mdm4
S Lam et al efficacy of chemotherapeutic agents to induce apoptosis in a subset of cancer cells in a p53-dependent manner, but additional, yet undetermined factors determine the final outcome of the treatment. Activation of p53 would be beneficial in tumors harboring wild-type p53. Conventional chemotherapeutic agents cause DNA damage, thereby targeting Mdm2 and Mdm4 resulting in activation of p53 . Treatment of various breast cancer cell lines with conventional genotoxic chemotherapeutic agents indeed resulted in increased p53 levels with concomitant upregulation of two important downstream targets, PUMA and p21, thereby reducing cell growth and viability.
Another approach to activate p53 in tumor cells is based on the fact that a large proportion of tumors still expressing wild-type p53 show increased levels of Mdm2 or Mdm4, making those proteins attractive candidates for the development of anti-cancer drugs. Recently, Nutlin-3, RITA, and MI-219 have been identified in drug discovery screens for low molecular weight compounds capable of disrupting the Mdm2-p53 interaction (Issaeva et al., 2004; Vassilev et al., 2004; Shangary et al., 2008) . Whether Nutlin-3 can also disrupt the Mdm4-p53 interaction is still a matter of debate. We show here, by manipulating Mdm4 levels in a number of breast cancer cell lines expressing wild-type p53, that high Mdm4 levels can blunt the sensitivity to Nutlin-3, but in a strong cell line-dependent manner. Mdm4 protein levels per se have no predictive value regarding Nutlin-3 sensitivity. Clearly, factors additional to Mdm4 have a function in determining sensitivity to Nutlin-3. Interestingly, in this panel of cell lines, the sensitivity to RITA seemed to be inversely correlated with endogenous Mdm4 levels, but more experiments are needed to validate this conclusion.
It has been reported that basal levels of Mdm2 are important in determining the Nutlin-3 response, that is cells highly expressing Mdm2 are more prone for Nutlin-3-induced apoptosis, because of a more efficient degradation of Mdm4 (Tovar et al., 2006) . Indeed, we found that cells expressing highest levels of Mdm2 are most sensitive to Nutlin-3 treatment, whereas cell lines with lower Mdm2 expression were less responsive. However, knock down of Mdm4 resulted in a stronger Mdm2 induction after Nutlin-3 treatment, whereas Mdm4 overexpression reduced Nutlin-3-induced Mdm2, especially in cell lines in which Mdm4 manipulation had no influence on Nutlin-3 sensitivity. Furthermore, no correlation was found between downregulation of Mdm4 and sensitivity on Nutlin-3 treatment. These findings confirm a recent report in which it was shown that neither endogenous Mdm2 nor Mdm4 levels in cancer cells correlate with Nutlin-3 sensitivity (Kitagawa et al., 2008) . These authors also proposed that E2F-1 activity is a critical determinant for Nutlin-3-induced apoptosis, which would explain why retinoblastoma cell lines are sensitive to Nutlin-3-induced apoptosis in spite of expressing high levels of Mdm4 (Laurie et al., 2006) . Furthermore, these authors show that the downregulation of E2F-1 observed in wild-type p53 cells on Nutlin-3 treatment is dependent on pRB expression (Kitagawa et al., 2008) . As treatment with Nutlin-3 strongly reduced E2F-1 levels in the breast cancer cells tested here (data not shown), an involvement of E2F-1 activity in the distinct sensitivity of the cell lines for Nutlin-3 seems unlikely.
In general, the p53 downstream targets p21 and PUMA were upregulated similarly on Mdm4 knock down, which can explain the growth inhibition of these cells. However, this effect could not explain the differential effect of Mdm4 manipulation on the sensitivity to Nutlin-3. It has been suggested that high levels of Mdm4 inhibit the p53-mediated induction of pro-apoptotic target genes, in that way preventing the induction of apoptosis by Nutlin-3 (Wade et al., 2008) . In this study, PARP cleavage was analyzed as marker for caspase-mediated apoptosis (Nicholson et al., 1995; Tewari et al., 1995; Oliver et al., 1998) . PARP cleavage was indeed increased after Nutlin-3 treatment in three of the four cell lines, suggesting that apoptosis was induced. Interestingly, knock down of Mdm4 increased PARP cleavage only in those cell lines, which were sensitized for Nutlin-3. These results suggest that Mdm4 indeed can protect cells from p53 dependent, Nutlin-3-induced apoptosis, but in a cell line-dependent manner.
Conventional chemotherapy is associated with undesirable and severe side effects (Shapiro and Recht, 2001 ). This favors a reduction of the dose of the chemotherapeutic agent to prevent the side effects without losing its effect as anti-cancer drug. Earlier studies have shown that Nutlin-3 is a potent sensitizer for standard radio-and chemotherapy (Barbieri et al., 2006; Cao et al., 2006; Coll-Mulet et al., 2006; Patton et al., 2006) . Therefore, Nutlin-3 was combined with doxorubicin, which resulted in increased cell death, even with concentrations of doxorubicin that by itself had very little effect on cell survival. Thus, combined treatment of doxorubicin with Nutlin-3 may allow dose reduction of the genotoxic compound to reduce side effects, whereas retaining the same anti-cancer effect or may even result in a more efficient decrease in cell viability of breast cancer cells.
In conclusion, we have shown that high Mdm4 levels may render a subset of breast cancer cells more resistant to various anti-cancer agents, but additional, Mdm4-independent factors also influence the drug response. Even so, targeting Mdm4 to sensitize tumor cells for conventional chemotherapeutic drugs might be a strategy to effectively treat tumors harboring wildtype p53.
Materials and methods
Cell culture and drug treatments MCF-7 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) and MPE600, ZR75-1, and ZR75-30 were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA). All culture media were supplemented with 10% FCS and antibiotics. MCF-10A1 cells were maintained in DMEM/ F-12 supplemented with 5% horse serum (both purchased at Invitrogen), 20 ng/ml epidermal growth factor (Upstate Biotechnology, Lake Placid, NY, USA), 100 mg/ml cholera enterotoxin, 5 mg/ml hydrocortisone, 10 mg/ml insulin (all purchased at Sigma-Aldrich, St Louis, MO, USA). Cells were seeded 24 h before treatment with Nutlin-3 (Cayman Chemical, Ann Arbor, MI, USA), doxorubicin (Sigma-Aldrich), N-phosphonacetyl-L-aspartate (PALA) (NCI), RITA (kind gift of Dr G Selivanova), etoposide (Sigma-Aldrich), or 5-fluorouracil (5-FU) (Sigma-Aldrich) at indicated concentrations and time points.
Plasmids and lentiviral infections
For the generation of a lentiviral expression vector for Mdm4, HA-Mdm4 (de Graaf et al., 2003) was cloned into pLV-CMVbc-GFP (Oruetxebarria et al., 2004) Table 1 for sequences). Subsequently, fragments containing the H1-promoter and cloned nucleotides were recloned into the PstI site of the lentiviral pRRL-CMV-GFP vector (Carlotti et al., 2004) . Production of lentiviruses by transfection into 293T cells has been described earlier (Carlotti et al., 2004) . For lentiviral infections, cells were seeded 24 h before. To obtain Mdm4 overexpression, cells were infected with HA-tagged Mdm4-expressing lentiviruses. To obtain specific knock down, cells were infected with Mdm4-or p53-shRNA-expressing lentiviruses; shRNA specifically targeting murine Mdm4 was used as negative control. For all infections, a multiplicity of infection of 1.5 was used. Cells were transduced overnight in the presence of 8 mg/ml polybrene (Sigma-Aldrich). The next day, the medium was replaced with fresh medium. Transduced cells were seeded for experimental purposes 3 to 4 days posttransduction.
Proliferation assay
Cell viability was measured using a WST-1 assay (Roche Biochemicals, Indianapolis, IN, USA). Briefly, cells were seeded in 96-well flat-bottom plates (Greiner Bio-One, Frickenhausen, Germany) in 100 ml of culture medium 24 h before drug treatments. Cell densities were as follows: MCF-7: 1500 cells/well, MPE600 and ZR75-1: 5000 cells/well, ZR75-30: 10 000 cells/well, and MCF-10A1: 1000 cells/well. After 0, 24, 48, and 72 h of drug treatment, 10 ml of WST-1 reagent was added and plates were further incubated up to 4 h at 37 1C. Absorbance was measured at 450 nm using a plate reader (Victor3 Multilabel Counter 1420-042, Perkin-Elmer, Wellesley, MA, USA).
Immunoblotting and antibodies
Cells were lysed in Giordano buffer (50 mM Tris-HCl (pH 7.4), 250 mM NaCl, 0.1% Triton X-100, and 5 mM EDTA) with 15% glycerol and protease and phosphatase inhibitors. Protein content was determined using Bradford Reagent (Biorad, Hercules, CA, USA) and equal amounts of protein were separated by SDS-PAGE. Proteins were transferred onto polyvinyldene difluoride membranes (Immobilon-P, Millipore, Bedford, MA, USA). Membranes were blocked in Trisbuffered saline, 0.2% Tween-20 (TBST) containing 10% non-fat dry milk, and subsequently incubated with the appropriate primary antibody. Membranes were washed three times with TBST and incubated with either horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary antibody (Jackson Laboratories, West Grove, PA, USA). After three times washing with TBST, proteins were detected by enhanced chemiluminescense (Super Signal West Dura, Peirce Biotechnology, Rockford, IL, USA) and visualized by exposure to X-ray film (Fujifilm Europe GmbH, Du¨sselford, Germany) or with the use of the Chemigenius XE3 (SynGene, Cambridge, UK). The following primary antibodies were used: rabbit anti-Mdm4 (BL1258, Bethyl Laboratories, Montgomery, TX, USA), mouse anti-Mdm2 (mixture of 4B2 (kind gift of Dr A Levine) and SMP14 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-p53 (DO-1, Santa Cruz Biotechnology), rabbit anti-phospho-p53 (Ser15 and Ser46, Cell Signaling Technologies, Beverly, MA, USA), rabbit anti-PUMA (Sigma-Aldrich), mouse anti-p21 (CP74, Upstate Biotechnology), mouse anti-a-tubulin (SigmaAldrich), mouse anti-g-tubulin (Sigma-Aldrich), rabbit anti-HAUSP (BL851, Bethyl Laboratories), rabbit anti-PARP (Cell Signaling Technology), mouse anti-pRB (G3-245, BD Pharmingen, San Diego, CA, USA), mouse anti-E2F-1 (clone KH95, Santa Cruz Biotechnology), rabbit anti-Cyclin D1 (06-137, Upstate Biotechnology), mouse anti-CDK4 (DCS-35, Abcam, Cambridge, MA, USA), and mouse anti-p16 (JC8, kind gift of Dr G Peters). The intensity of protein bands was determined by densitometry using GeneTools software (SynGene). Data analysis was performed by calculating protein levels relative to those of HAUSP or a-tubulin.
Statistical analysis
Data are presented as means ± s.d. of triplicate cultures and are representative of at least two independent experiments. Differences between various conditions were evaluated by ANOVA with a Bonferroni correction for multiple comparison. In some experiments, relative differences were tested with a two-tailed paired t-test. A value of Po0.05 was considered to represent a significant difference.
